Updates in CAR T Cell Therapies
During this presentation of the Cancer Moonshot Seminar Series, Carl June, M.D. (University of Pennsylvania) discusses updates in chimeric antigen receptor (CAR) T cell therapies and his Immuno-Oncology Translational Network (IOTN) research. This work is related to the Blue Ribbon Panel recommendation to create an adult immunotherapy network. https://www.cancer.gov/research/key-i...
▶︎
Center for Cancer Research Focus RT Clinical Trial for Prostate Cancer: Frequently Asked Questions
▶︎
Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
▶︎
Introducing the Breast Cancer Symptom Explorer: Visualizing Adverse Events and Quality of Life
▶︎
Risk Factors for Cancer | Did You Know?
▶︎
How Patient-Reported Bother by Side Effects Predicts Cancer Treatment Discontinuation
▶︎
Neuro-Oncology Branch Shapes the Next Generation of Researchers and Clinicians
▶︎
Understanding the Toxicity Index: A Superior Measure for Adverse Event Analysis
▶︎
Improving Cancer Care for Older Adults: The Role of Geriatric Assessments
![Your National Cancer Institute. Driving Cancer Breakthroughs. [Extended Version]](https://i.ytimg.com/vi/qL2Ovw21oDA/hqdefault.jpg?sqp=-oaymwEjCNACELwBSFryq4qpAxUIARUAAAAAGAElAADIQj0AgKJDeAE=&rs=AOn4CLDzNVyiXytT8reoy7Pw-wzm0JbSow)
▶︎
Your National Cancer Institute. Driving Cancer Breakthroughs. [Extended Version]
▶︎
Lacey Koelling — CCR Patients Perspective
▶︎
Office of Cancer Survivorship Vision, Mission, and Future
▶︎
Childhood Cancer Data Initiative Hub Explore Dashboard Tutorial
▶︎
ProAE R Package: Advanced Tools for Patient-Reported Adverse Event Analysis in Clinical Trials
▶︎
Your National Cancer Institute. Driving Cancer Breakthroughs.
▶︎
International Cancer Proteogenome Consortium
▶︎